Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Elongin A CRISPR/Cas9 KO Plasmid (h): sc-404668
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Elongin A CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Elongin A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Elongin A Antibody (A-5): sc-373811
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Elongin A CRISPR/Cas9 KO Plasmid (h) | sc-404668 | 20 µg | $397.00 |
Overview
ELOA encodes Elongin A, a core component of the Elongin transcription elongation complex that enhances RNA polymerase II processivity and helps coordinate productive mRNA synthesis. Elongin A also participates in transcription-coupled ubiquitin ligase assemblies, linking elongation control with protein turnover and cellular stress responses. Through these roles, ELOA influences gene expression programs governing proliferation, DNA damage responses, and adaptation to proteotoxic conditions. Dysregulation of transcription elongation and ubiquitin-mediated regulation are recurrent features in cancer and neurodevelopmental phenotypes, making ELOA a useful node for mechanistic studies of these pathways.
Elongin A CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ELOA gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ELOA together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ELOA open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Elongin A protein expression.
This CRISPR knockout system enables efficient generation of ELOA-deficient cell models for investigation of Elongin A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ELOA exon(s) critical for Elongin A function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ELOA genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Elongin A CRISPR/Cas9 KO Plasmid (h) and Elongin A CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ELOA locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Elongin A HDR Plasmid (h) and Elongin A HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ELOA homology arms to support homology-directed repair at defined ELOA target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.